AecorBio develops peptide therapeutics to normalize dysregulated gene expression in oncology, immunology, and neurology, aiming to restore responses to standard treatments. Its lead drug targets metastatic castration-resistant prostate cancer (mCRPC) in combination with androgen receptor pathway inhibitors, with plans to expand to earlier-stage CRPC.
Hofseth Biocare ASA sells a USD 5 million stake in its subsidiary Aecorbio. The transaction involves a partial divestment of ownership in the biotech company. Hofseth Biocare focuses on developing medical devices and biopharmaceuticals, while Aecorbio specializes in regenerative medicine solutions.
AECORBIO raises an additional $1.5 million in funding, bringing its valuation to $30 million. The company advances its FT-002A peptide-based therapy in development for prostate cancer treatment. This latest investment supports ongoing research and clinical progress for the experimental drug.
HBC Immunology finalizes in vivo testing of its lead peptide **FT-002a** in an oral formulation combined with enzalutamide (Xtandi®), a leading androgen receptor inhibitor. The studies show FT-002a enhances anti-tumor effects in models of both indolent and aggressive prostate cancers. The drug candidate is developed under Hofseth Biocare ASA’s HBC Immunology division.
Hofseth Biocare ASA identifies a novel drug candidate targeting asthma and transfers ownership to its subsidiary, HBC Immunology Inc. The move aims to advance the candidate’s development under the immunology-focused division. The company specializes in respiratory and immune-related therapies.
Hofseth Biocare ASA emerges as a spin-off company focused on developing co-treatment solutions for prostate cancer. The initiative originates from a dedicated research project targeting advanced therapeutic approaches. The company aims to leverage scientific advancements to address unmet medical needs in prostate cancer care.